JADPRO Live 2019 Activities
JADPRO Live 2018 Activities
MPN Resource Center
Myelofibrosis: Narratives on Collaboration
Relapsed/Refractory Multiple Myeloma
Management of irAEs
Managing Classical Hodgkin Lymphoma
Updates in Heme Malignancy Side Effects
Narratives: HER2-Positive Breast Cancer
Learn more on this topic:
Overview of Immunotherapy
Why is pseudo-progression an important issue in patients on immune checkpoint inhibitors?
Laura J. Zitella, MS, RN, ACNP-BC, AOCN
Is programmed cell death ligand 1 (PD-L1) testing necessary?
When should you image patients to assess response to immunotherapy?
What are the mechanisms of action and adverse effects of these agents?
How do responses to immune checkpoint inhibitors differ from responses to chemotherapy?
What cancers are most likely to respond to immunotherapy?
How do you educate patients about the timing of early and latent side effects?
Copyright © 2010-2019 Harborside Press, LLC All rights reserved.
Bot trap - Don't go here
to learn more.